$CARM
Carisma Therapeutics Inc

2017 Q4 Form 10-Q Financial Statement

#000148500317000145 Filed on November 17, 2017

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2016 Q4
Revenue $0.00 $0.00 $825.0K
YoY Change -100.0% -100.0% 46.02%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.990M $1.630M $2.750M
YoY Change -27.64% -74.41% 18.53%
% of Gross Profit
Research & Development $3.110M $3.619M $2.800M
YoY Change 11.07% 31.41% -65.35%
% of Gross Profit
Depreciation & Amortization $70.00K $50.00K $70.00K
YoY Change 0.0% 150.0% -12.5%
% of Gross Profit
Operating Expenses $6.593M $9.150M $4.447M
YoY Change 48.26% 0.33% -57.25%
Operating Profit -$6.593M -$9.150M -$3.622M
YoY Change 82.03% -146.85% -63.18%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $50.00K $45.00K -$820.0K
YoY Change -106.1% -204.65% 1071.43%
Pretax Income -$6.550M -$9.110M -$3.530M
YoY Change 85.55% -146.74% -65.83%
Income Tax $0.00 $10.00K
% Of Pretax Income
Net Earnings -$6.547M -$9.105M -$3.531M
YoY Change 85.41% -146.72% -65.81%
Net Earnings / Revenue -428.0%
Basic Earnings Per Share -$0.37 -$0.15
Diluted Earnings Per Share -$215.2K -$0.37 -$0.15
COMMON SHARES
Basic Shares Outstanding 31.83M shares 24.69M shares 24.24M shares
Diluted Shares Outstanding 24.69M shares

Balance Sheet

Concept 2017 Q4 2017 Q3 2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.70M $11.30M $25.30M
YoY Change -41.9% -63.19% -29.92%
Cash & Equivalents $14.68M $11.34M $25.34M
Short-Term Investments
Other Short-Term Assets $300.0K $800.0K $600.0K
YoY Change -50.0% -27.27% 200.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $14.98M $12.11M $25.93M
YoY Change -42.22% -61.94% -28.6%
LONG-TERM ASSETS
Property, Plant & Equipment $522.0K $585.0K $796.0K
YoY Change -34.42% -34.56% 95.58%
Goodwill $13.06M $13.06M $16.86M
YoY Change -22.53% 26.69%
Intangibles $46.40M $46.40M $60.50M
YoY Change -23.31% 28.18%
Long-Term Investments
YoY Change
Other Assets $120.0K $101.0K $0.00
YoY Change -71.14% -100.0%
Total Long-Term Assets $60.12M $60.16M $78.17M
YoY Change -23.1% 25.95% 15108.17%
TOTAL ASSETS
Total Short-Term Assets $14.98M $12.11M $25.93M
Total Long-Term Assets $60.12M $60.16M $78.17M
Total Assets $75.10M $72.27M $104.1M
YoY Change -27.86% -9.19% 182.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $907.0K $1.366M $1.667M
YoY Change -45.59% -22.43% 33.79%
Accrued Expenses $3.813M $2.915M $1.774M
YoY Change 114.94% 16.97% -1.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $4.720M $4.404M $3.980M
YoY Change 18.59% -29.7% -47.49%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $215.0K $170.0K $0.00
YoY Change -100.0%
Total Long-Term Liabilities $215.0K $170.0K $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.720M $4.404M $3.980M
Total Long-Term Liabilities $215.0K $170.0K $0.00
Total Liabilities $4.935M $4.574M $3.980M
YoY Change 23.99% -26.99% -50.27%
SHAREHOLDERS EQUITY
Retained Earnings -$152.3M -$145.8M -$123.3M
YoY Change 23.53% 21.72% -1.51%
Common Stock $35.00K $25.00K $25.00K
YoY Change 40.0% 4.17% 25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.03M $17.07M $38.68M
YoY Change
Total Liabilities & Shareholders Equity $75.10M $72.27M $104.1M
YoY Change -27.86% -9.19% 182.68%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2016 Q4
OPERATING ACTIVITIES
Net Income -$6.547M -$9.105M -$3.531M
YoY Change 85.41% -146.72% -65.81%
Depreciation, Depletion And Amortization $70.00K $50.00K $70.00K
YoY Change 0.0% 150.0% -12.5%
Cash From Operating Activities -$3.630M -$4.430M -$5.520M
YoY Change -34.24% -120.41% -41.15%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $20.00K $10.00K $40.00K
YoY Change -50.0% -97.62%
Cash From Investing Activities $20.00K $10.00K $40.00K
YoY Change -50.0% -97.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.960M 0.000 100.0K
YoY Change 6860.0% -100.0% -111.11%
NET CHANGE
Cash From Operating Activities -3.630M -4.430M -5.520M
Cash From Investing Activities 20.00K 10.00K 40.00K
Cash From Financing Activities 6.960M 0.000 100.0K
Net Change In Cash 3.350M -4.420M -5.380M
YoY Change -162.27% -119.87% -47.67%
FREE CASH FLOW
Cash From Operating Activities -$3.630M -$4.430M -$5.520M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
94000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
14000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-915000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Period End Date
DocumentPeriodEndDate
2017-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001485003
CY2017Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31831995 shares
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Entity Registrant Name
EntityRegistrantName
Eleven Biotherapeutics, Inc.
dei Trading Symbol
TradingSymbol
EBIO
CY2017Q3 ebio Working Capital Net
WorkingCapitalNet
7700000 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1667000 USD
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1366000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1774000 USD
CY2017Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2915000 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
413000 USD
CY2017Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
244000 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
161963000 USD
CY2017Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
162825000 USD
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2686374 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2782613 shares
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2900906 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2900906 shares
CY2016Q4 us-gaap Assets
Assets
104097000 USD
CY2017Q3 us-gaap Assets
Assets
72268000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
25927000 USD
CY2017Q3 us-gaap Assets Current
AssetsCurrent
12108000 USD
CY2016Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0 USD
CY2017Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
3900000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
7600000 USD
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
45100000 USD
CY2017Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
38100000 USD
us-gaap Business Combination Provisional Information Initial Accounting Incomplete Adjustment Consideration Transferred
BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred
0 USD
us-gaap Business Combination Provisional Information Initial Accounting Incomplete Adjustment Consideration Transferred
BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred
14600000 USD
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
136000 USD
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36079000 USD
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30716000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25342000 USD
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11338000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5363000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-14004000 USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
852000 USD
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24531964 shares
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24698135 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24531964 shares
CY2017Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24698135 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
25000 USD
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
25000 USD
CY2017Q3 us-gaap Construction Payable Current
ConstructionPayableCurrent
2156000 USD
CY2016Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
16335000 USD
CY2017Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
12528000 USD
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
425000 USD
CY2017Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
111000 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
221000 USD
CY2016Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
5000 USD
CY2017Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 USD
CY2016Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
114000 USD
CY2017Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
123000 USD
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.95
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.27
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.91
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.26
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
352000 USD
CY2017Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
453000 USD
CY2016Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
64000 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-38000 USD
CY2017Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5000 USD
CY2016 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0
CY2016 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P11M1D
us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P2M1D
CY2016 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.8339
us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.6004
CY2016 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0085
us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0096
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
48568000 USD
us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
0 USD
CY2016Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
9000 USD
CY2017Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6366000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11984000 USD
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1631000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6085000 USD
CY2016Q4 us-gaap Goodwill
Goodwill
16864000 USD
CY2017Q3 us-gaap Goodwill
Goodwill
13064000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-648000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-301000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1189000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
803000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
844000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-425000 USD
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-62000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
285000 USD
us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
10000 USD
CY2016Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2017Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
60500000 USD
CY2017Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
46400000 USD
CY2016Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
0 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-247000 USD
CY2017Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
0 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
0 USD
us-gaap Interest Paid
InterestPaid
663000 USD
us-gaap Interest Paid
InterestPaid
0 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
104097000 USD
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
72268000 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
13279000 USD
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
0 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3980000 USD
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4404000 USD
CY2016Q3 us-gaap License And Maintenance Revenue
LicenseAndMaintenanceRevenue
0 USD
us-gaap License And Maintenance Revenue
LicenseAndMaintenanceRevenue
406000 USD
CY2017Q3 us-gaap License And Maintenance Revenue
LicenseAndMaintenanceRevenue
0 USD
us-gaap License And Maintenance Revenue
LicenseAndMaintenanceRevenue
0 USD
CY2016Q3 us-gaap Licenses Revenue
LicensesRevenue
28650000 USD
us-gaap Licenses Revenue
LicensesRevenue
28750000 USD
CY2017Q3 us-gaap Licenses Revenue
LicensesRevenue
0 USD
us-gaap Licenses Revenue
LicensesRevenue
425000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-13920000 USD
us-gaap Operating Expenses
OperatingExpenses
22668000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
52000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
419000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
84000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
8138000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14140000 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
19487000 USD
us-gaap Net Income Loss
NetIncomeLoss
5422000 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-9105000 USD
us-gaap Net Income Loss
NetIncomeLoss
-22482000 USD
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-43000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1066000 USD
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
45000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
180000 USD
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
9120000 USD
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
9150000 USD
us-gaap Operating Expenses
OperatingExpenses
23087000 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
19530000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
6488000 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9150000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-22662000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
157000 USD
CY2017Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
62000 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 USD
CY2017Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
101000 USD
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2017Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
170000 USD
CY2016Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-43000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
96000 USD
CY2017Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
45000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
180000 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
26000 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
0 USD
us-gaap Payments For Restructuring
PaymentsForRestructuring
28000 USD
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
585000 USD
CY2017Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
770000 USD
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
283000 USD
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
84000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
204000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
40000 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0 USD
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
12000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
796000 USD
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
585000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
14124000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2754000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10684000 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3619000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9402000 USD
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
10000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3351000 USD
CY2017Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
10000 USD
CY2017Q3 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
200000 USD
us-gaap Restructuring Charges
RestructuringCharges
188000 USD
CY2016Q4 us-gaap Restructuring Reserve
RestructuringReserve
31000 USD
CY2017Q3 us-gaap Restructuring Reserve
RestructuringReserve
191000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-123311000 USD
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-145784000 USD
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-145800000 USD
CY2016Q3 us-gaap Sales Revenue Net
SalesRevenueNet
28650000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
29156000 USD
CY2017Q3 us-gaap Sales Revenue Net
SalesRevenueNet
0 USD
us-gaap Sales Revenue Net
SalesRevenueNet
425000 USD
CY2016Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2144000 USD
CY2017Q3 us-gaap Share Based Compensation
ShareBasedCompensation
253000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
819000 USD
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1161259 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.51
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
166887 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
248025 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2024468 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1965206 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.41
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.92
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1965206 shares
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.92
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.28
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
9.85
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.85
us-gaap Stock Issued1
StockIssued1
13525000 USD
us-gaap Stock Issued1
StockIssued1
0 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
140400 shares
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
38677000 USD
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
17066000 USD
CY2016Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
928404 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
791736 shares
CY2017Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
21423000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20796000 shares
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24691000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
24663000 shares
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20495000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20004000 shares
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24691000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
24663000 shares
us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
221000 USD
us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
0 USD

Files In Submission

Name View Source Status
0001485003-17-000145-index-headers.html Edgar Link pending
0001485003-17-000145-index.html Edgar Link pending
0001485003-17-000145.txt Edgar Link pending
0001485003-17-000145-xbrl.zip Edgar Link pending
ebio-093017x10q.htm Edgar Link pending
ebio-093017x311.htm Edgar Link pending
ebio-093017x312.htm Edgar Link pending
ebio-093017x321.htm Edgar Link pending
ebio-20170930.xml Edgar Link completed
ebio-20170930.xsd Edgar Link pending
ebio-20170930_cal.xml Edgar Link unprocessable
ebio-20170930_def.xml Edgar Link unprocessable
ebio-20170930_lab.xml Edgar Link unprocessable
ebio-20170930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending